Avadomide Explained

Legal Status:	Investigational
Cas Number:	1015474-32-4
Unii:	28DZS29F59
Pubchem:	24967599
Drugbank:	DB14857
Chembl:	3989934
Chemspiderid:	35521266
Iuphar Ligand:	10522
Kegg:	D11132
Iupac Name:	3-(5-Amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione
Stdinchi:	1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
Stdinchikey:	RSNPAKAFCAAMBH-UHFFFAOYSA-N
Smiles:	CC1=NC2=CC=CC(=C2C(=O)N1C3CCC(=O)NC3=O)N
C:	14
H:	14
N:	4
O:	3

Avadomide is an experimental cereblon E3 ligase modulator, or thalidomide analog studied to see if it is effective against cancer.^{[1] [2] [3] [4] [5] [6]}

Notes and References

1. Nishi . Hidemi . Gotoh . Kunihito . Tomimaru . Yoshito . Kobayashi . Shogo . Sasaki . Kazuki . Iwagami . Yoshifumi . Yamada . Daisaku . Akita . Hirofumi . Asaoka . Tadafumi . Noda . Takehiro . Takahashi . Hidenori . Tanemura . Masahiro . Doki . Yuichiro . Eguchi . Hidetoshi . Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma . Cancer Chemotherapy and Pharmacology . October 2023 . 92 . 4 . 303–314 . 10.1007/s00280-023-04531-w. 37491611 . 10435408 .
2. Nastoupil . Loretta J. . Kuruvilla . John . Chavez . Julio C. . Bijou . Fontanet . Witzig . Thomas E. . Santoro . Armando . Flinn . Ian W. . Boccomini . Carola . Kenkre . Vaishalee P. . Corradini . Paolo . Isufi . Iris . Andorsky . David J. . Klein . Leonard M. . Greenwald . Daniel R. . Sangha . Randeep . Shen . Frank . Hagner . Patrick . Li . Yan . Dobmeyer . Juergen . Gong . Nian . Uttamsingh . Shailaja . Pourdehnad . Michael . Ribrag . Vincent . Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma . EJHaem . May 2022 . 3 . 2 . 394–405 . 10.1002/jha2.394. 35846031 . 9175947 .
3. Heim . Christopher . Hartmann . Marcus D. . High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system . Acta Crystallographica Section D Structural Biology . 1 March 2022 . 78 . 3 . 290–298 . 10.1107/S2059798322000092. 35234143 . 8900816 . 2022AcCrD..78..290H .
4. Hagner . Patrick R. . Chiu . Hsiling . Chopra . Vivek S. . Colombo . Martino . Patel . Nisha . Estevez . Maria Ortiz . Waldman . Michelle F. . Loos . Remco . Towfic . Fadi . Gandhi . Anita K. . Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL . Clinical Cancer Research . 2 August 2022 . 28 . 15 . 3367–3377 . 10.1158/1078-0432.CCR-21-3347. 35583604 . 9662945 .
5. Santiesteban . Daniela Y . Duncan . Aundrietta D . Mirza . Nadeem Q . Jacques . Vincent . DeWitt . Sheila . Iyer . Swami P. . SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models . Blood . 15 November 2022 . 140 . Supplement 1 . 8865–8866 . 10.1182/blood-2022-167495. 254268049 . free .
6. Ribrag . Vincent . Chavez . Julio C. . Boccomini . Carola . Kaplan . Jason . Chandler . Jason C. . Santoro . Armando . Corradini . Paolo . Flinn . Ian W. . Advani . Ranjana . Cassier . Philippe A. . Sangha . Randeep . Kenkre . Vaishalee P. . Isufi . Iris . Uttamsingh . Shailaja . Hagner . Patrick R. . Gandhi . Anita K. . Shen . Frank . Michelliza . Sophie . Haeske . Harald . Hege . Kristen . Pourdehnad . Michael . Kuruvilla . John . Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma . EJHaem . February 2022 . 3 . 1 . 139–153 . 10.1002/jha2.375. 35846221 . 9176062 .